The cellular and signalling alterations conducted by TGF-β contributing to renal fibrosis

Cytokine

Volumn 88, Issue , 2016, Pages 115-125

  Vega, Génesis ^a   Alarcón, Sebastián ^a   San Martín, Rody ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

Chronic kidney disease; Myofibroblast; Renal fibrosis; Transforming growth factor

Indexed keywords

CHEMOKINE; CYTOKINE; DESMIN; FIBRILLAR COLLAGEN; FIBRONECTIN; GELATINASE A; HEPARIN; INTERLEUKIN 1BETA; LAMININ; MONOCYTE CHEMOTACTIC PROTEIN 1; PERLECAN; PROTEOGLYCAN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UVOMORULIN; VIMENTIN;

APOPTOSIS; CELLS BY BODY ANATOMY; CHRONIC KIDNEY DISEASE; EXTRACELLULAR MATRIX; FIBROGENESIS; GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; MESANGIUM CELL; MYOFIBROBLAST; PARENCHYMA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; FIBROSIS; KIDNEY TUBULE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; FIBROSIS; HUMANS; KIDNEY TUBULES; MYOFIBROBLASTS; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84984996793     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.08.019     Document Type: Review

References (162)

1. [1] Jha, V., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382:9888 (2013), 260–272.
2. [2] Duffield, J.S., et al. Host responses in tissue repair and fibrosis. Annu. Rev. Pathol. 8 (2013), 241–276.
3. [3] Campanholle, G., et al. Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am. J. Physiol. Cell Physiol. 304:7 (2013), C591–C603.
4. [4] Duffield, J.S., Cellular and molecular mechanisms in kidney fibrosis. J. Clin. Invest. 124:6 (2014), 2299–2306.
5. [5] Liu, Y., Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69:2 (2006), 213–217.
6. [6] Hirschberg, R., Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis. J. Am. Soc. Nephrol. 16:1 (2005), 9–11.
7. [7] Meng, X.M., Nikolic-Paterson, D.J., Lan, H.Y., Inflammatory processes in renal fibrosis. Nat. Rev. Nephrol. 10:9 (2014), 493–503.
8. [8] Bondi, C.D., et al. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J. Am. Soc. Nephrol. 21:1 (2010), 93–102.
9. [9] Chen, Y.T., et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int. 80:11 (2011), 1170–1181.
10. [10] Strutz, F., et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 57:4 (2000), 1521–1538.
11. [11] Song, J., EMT or apoptosis: a decision for TGF-beta. Cell Res. 17:4 (2007), 289–290.
12. [12] Grande, M.T., et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 21:9 (2015), 989–997.
13. [13] Humphreys, B.D., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176:1 (2010), 85–97.
14. [14] LeBleu, V.S., et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19:8 (2013), 1047–1053.
15. [15] Lin, S.L., et al. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173:6 (2008), 1617–1627.
16. [16] Wu, C.F., et al. Transforming growth factor beta-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am. J. Pathol. 182:1 (2013), 118–131.
17. [17] Iwano, M., et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110:3 (2002), 341–350.
18. [18] Lee, K., Nelson, C.M., New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. Int. Rev. Cell Mol. Biol. 294 (2012), 171–221.
19. [19] Lovisa, S., et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 21:9 (2015), 998–1009.
20. [20] Grgic, I., et al. Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int. 82:2 (2012), 172–183.
21. [21] Smith, S.W., Chand, S., Savage, C.O., Biology of the renal pericyte. Nephrol. Dial. Transplant. 27:6 (2012), 2149–2155.
22. [22] Lin, S.L., et al. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am. J. Pathol. 178:2 (2011), 911–923.
23. [23] Nikolic-Paterson, D.J., Wang, S., Lan, H.Y., Macrophages promote renal fibrosis through direct and indirect mechanisms. Kidney Int Suppl (2011) 4:1 (2014), 34–38.
24. [24] Wang, S., et al. TGF-beta/Smad3 signalling regulates the transition of bone marrow-derived macrophages into myofibroblasts during tissue fibrosis. Oncotarget 7:8 (2016), 8809–8822.
25. [25] Tan, R.J., Liu, Y., Macrophage-derived TGF-beta in renal fibrosis: not a macro-impact after all. Am. J. Physiol. Renal. Physiol. 305:6 (2013), F821–F822.
26. [26] Castro, N.E., et al. Transforming growth factor beta1 (TGF-beta1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells. J. Biol. Chem. 289:42 (2014), 29001–29013.
27. [27] Riser, B.L., et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 11:1 (2000), 25–38.
28. [28] Schlondorff, D., The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J. 1:4 (1987), 272–281.
29. [29] Bollineni, J.S., Reddi, A.S., Transforming growth factor-beta 1 enhances glomerular collagen synthesis in diabetic rats. Diabetes 42:11 (1993), 1673–1677.
30. [30] Kagami, S., et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 93:6 (1994), 2431–2437.
31. [31] Ziyadeh, F.N., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 97:14 (2000), 8015–8020.
32. [32] Schlondorff, D., Banas, B., The mesangial cell revisited: no cell is an island. J. Am. Soc. Nephrol. 20:6 (2009), 1179–1187.
33. [33] Kim, H., Cheigh, J.S., Kidney transplantation in patients with type 1 diabetes mellitus: long-term prognosis for patients and grafts. Korean J. Intern. Med. 16:2 (2001), 98–104.
34. [34] Asanuma, K., The role of podocyte injury in chronic kidney disease. Nihon Rinsho Meneki Gakkai Kaishi 38:1 (2015), 26–36.
35. [35] Reiser, J., Sever, S., Podocyte biology and pathogenesis of kidney disease. Annu. Rev. Med. 64 (2013), 357–366.
36. [36] Wiggins, J.E., et al. Podocyte hypertrophy, “adaptation,” and “decompensation” associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J. Am. Soc. Nephrol. 16:10 (2005), 2953–2966.
37. [37] Wharram, B.L., et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J. Am. Soc. Nephrol. 16:10 (2005), 2941–2952.
38. [38] Huynh, M.L., Fadok, V.A., Henson, P.M., Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 109:1 (2002), 41–50.
39. [39] Wang, W., et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J. Am. Soc. Nephrol. 16:5 (2005), 1371–1383.
40. [40] Cheng, X., et al. Both ERK/MAPK and TGF-Beta/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation. J. Diabetes Res., 2013, 2013, 463740.
41. [41] Liu, N., et al. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS ONE, 8(1), 2013, e54001.
42. [42] Xiao, L., et al. TGF-beta 1 induced fibroblast proliferation is mediated by the FGF-2/ERK pathway. Front Biosci. (Landmark Ed) 17 (2012), 2667–2674.
43. [43] Ding, Y., Choi, M.E., Regulation of autophagy by TGF-beta: emerging role in kidney fibrosis. Semin. Nephrol. 34:1 (2014), 62–71.
44. [44] Bottinger, E.P., Bitzer, M., TGF-beta signaling in renal disease. J. Am. Soc. Nephrol. 13:10 (2002), 2600–2610.
45. [45] Murakami, K., et al. Urinary transforming growth factor-beta in patients with glomerular diseases. Pediatr. Nephrol. 11:3 (1997), 334–336.
46. [46] Yamamoto, T., et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 49:2 (1996), 461–469.
47. [47] Zeisberg, M., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9:7 (2003), 964–968.
48. [48] Okada, H., et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273:4 Pt 2 (1997), F563–F574.
49. [49] Liu, F.Y., et al. Arkadia regulates TGF-beta signaling during renal tubular epithelial to mesenchymal cell transition. Kidney Int. 73:5 (2008), 588–594.
50. [50] Kretschmar, C., et al. Reduced adenosine uptake and its contribution to signaling that mediates profibrotic activation in renal tubular epithelial cells: implication in diabetic nephropathy. PLoS ONE, 11(1), 2016, e0147430.
51. [51] Oyarzun, C., et al. Increased levels of adenosine and ecto 5′-nucleotidase (CD73) activity precede renal alterations in experimental diabetic rats. Biochem. Biophys. Res. Commun. 468:1–2 (2015), 354–359.
52. [52] Boutet, A., et al. Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J. 25:23 (2006), 5603–5613.
53. [53] Munger, J.S., et al. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 51:5 (1997), 1376–1382.
54. [54] Nunes, I., et al. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J. Cell Biol. 136:5 (1997), 1151–1163.
55. [55] Ramirez, F., Sakai, L.Y., Biogenesis and function of fibrillin assemblies. Cell Tissue Res. 339:1 (2010), 71–82.
56. [56] Cheng, S., Lovett, D.H., Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am. J. Pathol. 162:6 (2003), 1937–1949.
57. [57] Daniel, C., et al. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int. 65:2 (2004), 459–468.
58. [58] Wahab, N.A., et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48:12 (2005), 2650–2660.
59. [59] Wipff, P.J., Hinz, B., Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur. J. Cell Biol. 87:8–9 (2008), 601–615.
60. [60] Murphy, S.J., et al. Differential trafficking of transforming growth factor-beta receptors and ligand in polarized epithelial cells. Mol. Biol. Cell 15:6 (2004), 2853–2862.
61. [61] Moyano, J.V., et al. Autocrine transforming growth factor-{beta}1 activation mediated by integrin {alpha}V{beta}3 regulates transcriptional expression of laminin-332 in Madin-Darby canine kidney epithelial cells. Mol. Biol. Cell 21:21 (2010), 3654–3668.
62. [62] Hahm, K., et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am. J. Pathol. 170:1 (2007), 110–125.
63. [63] Trevillian, P., et al. Alpha(v)beta(6) Integrin expression in diseased and transplanted kidneys. Kidney Int. 66:4 (2004), 1423–1433.
64. [64] Yeh, Y.C., et al. Transforming growth factor-{beta}1 induces Smad3-dependent {beta}1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. Am. J. Pathol. 177:4 (2010), 1743–1754.
65. [65] Dockrell, M.E., Phanish, M.K., Hendry, B.M., Tgf-beta auto-induction and connective tissue growth factor expression in human renal tubule epithelial cells requires N-ras. Nephron Exp. Nephrol. 112:3 (2009), e71–e79.
66. [66] Grande, J.P., et al. TGF-beta1 is an autocrine mediator of renal tubular epithelial cell growth and collagen IV production. Exp. Biol. Med. (Maywood) 227:3 (2002), 171–181.
67. [67] McCartney-Francis, N., et al. TGF-beta regulates production of growth factors and TGF-beta by human peripheral blood monocytes. Growth Factors 4:1 (1990), 27–35.
68. [68] Kim, S.J., et al. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol. Cell. Biol. 10:4 (1990), 1492–1497.
69. [69] Abbate, M., et al. Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int. 61:6 (2002), 2066–2077.
70. [70] Li, R., et al. The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-beta/Smad3-Azin1 pathway. Kidney Int. 84:6 (2013), 1129–1144.
71. [71] Samarakoon, R., et al. TGF-beta1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res. 347:1 (2012), 117–128.
72. [72] Fujimoto, M., et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 305:4 (2003), 1002–1007.
73. [73] Chen, H.Y., et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60:2 (2011), 590–601.
74. [74] Sato, M., et al. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112:10 (2003), 1486–1494.
75. [75] Fukasawa, H., et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc. Natl. Acad. Sci. U. S. A. 101:23 (2004), 8687–8692.
76. [76] Li, J.H., et al. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J. Am. Soc. Nephrol. 13:6 (2002), 1464–1472.
77. [77] Meng, X.M., et al. Disruption of Smad4 impairs TGF-beta/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int. 81:3 (2012), 266–279.
78. [78] Phanish, M.K., et al. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem. J. 393:Pt 2 (2006), 601–607.
79. [79] Sutaria, P.M., et al. Transforming growth factor-beta receptor types I and II are expressed in renal tubules and are increased after chronic unilateral ureteral obstruction. Life Sci. 62:21 (1998), 1965–1972.
80. [80] Wang, B., et al. Transforming growth factor-beta1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. 85:2 (2014), 352–361.
81. [81] Yang, J., Liu, Y., Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J. Am. Soc. Nephrol. 13:1 (2002), 96–107.
82. [82] Xiong, M., et al. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am. J. Physiol. Renal. Physiol. 302:3 (2012), F369–F379.
83. [83] Peinado, H., Quintanilla, M., Cano, A., Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem. 278:23 (2003), 21113–21123.
84. [84] Hu, B., Wu, Z., Phan, S.H., Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression. Am. J. Respir. Cell Mol. Biol. 29:3 Pt 1 (2003), 397–404.
85. [85] Fausther, M., et al. Activated hepatic stellate cells upregulate transcription of ecto-5′-nucleotidase/CD73 via specific SP1 and SMAD promoter elements. Am. J. Physiol. Gastrointest. Liver Physiol. 303:8 (2012), G904–G914.
86. [86] Cardenas, A., et al. Adenosine A(2B) receptor-mediated VEGF induction promotes diabetic glomerulopathy. Lab. Invest. 93:1 (2013), 135–144.
87. [87] Peng, Z., et al. Ecto-5′-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. Nucleosides, Nucleotides Nucleic Acids 27:6 (2008), 821–824.
88. [88] Xia, J.F., et al. Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients. Clin. Biochem. 42:3 (2009), 215–220.
89. [89] Lee, J., et al. The selective A3AR antagonist LJ-1888 ameliorates UUO-induced tubulointerstitial fibrosis. Am. J. Pathol. 183:5 (2013), 1488–1497.
90. [90] Qin, W., et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22:8 (2011), 1462–1474.
91. [91] Maurer, B., et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62:6 (2010), 1733–1743.
92. [92] Cushing, L., et al. MiR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 45:2 (2011), 287–294.
93. [93] van Rooij, E., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 105:35 (2008), 13027–13032.
94. [94] Meng, X.M., et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J. Am. Soc. Nephrol. 21:9 (2010), 1477–1487.
95. [95] Oba, S., et al. MiR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS ONE, 5(10), 2010, e13614.
96. [96] Phanish, M.K., et al. TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp. Nephrol. 100:4 (2005), e156–e165.
97. [97] Wang, S., et al. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int. 60:1 (2001), 96–105.
98. [98] Zhang, P., et al. Activation of Wnt11 by transforming growth factor-beta drives mesenchymal gene expression through non-canonical Wnt protein signaling in renal epithelial cells. J. Biol. Chem. 287:25 (2012), 21290–21302.
99. [99] Piek, E., et al. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem. 276:23 (2001), 19945–19953.
100. [100] Nakao, A., et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389:6651 (1997), 631–635.
101. [101] Shi, W., et al. GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor. J. Cell Biol. 164:2 (2004), 291–300.
102. [102] Di Guglielmo, G.M., et al. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol. 5:5 (2003), 410–421.
103. [103] Lan, H.Y., et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J. Am. Soc. Nephrol. 14:6 (2003), 1535–1548.
104. [104] Zhong, X., et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J. Am. Soc. Nephrol. 22:9 (2011), 1668–1681.
105. [105] McClelland, A.D., et al. MiR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin. Sci. (Lond.) 129:12 (2015), 1237–1249.
106. [106] Yu, Z., et al. BMP-7 Attenuates TGF-beta1-induced fibronectin secretion and apoptosis of NRK-52E cells by the suppression of miRNA-21. Oncol. Res. 23:4 (2016), 147–154.
107. [107] Veerasamy, M., et al. Differential regulation of E-cadherin and alpha-smooth muscle actin by BMP 7 in human renal proximal tubule epithelial cells and its implication in renal fibrosis. Am. J. Physiol. Renal. Physiol. 297:5 (2009), F1238–F1248.
108. [108] Imamura, T., et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389:6651 (1997), 622–626.
109. [109] Samavarchi-Tehrani, P., et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 7:1 (2010), 64–77.
110. [110] Nguyen, T.Q., et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol. 19:11 (2008), 2098–2107.
111. [111] Dolan, V., et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am. J. Kidney Dis. 45:6 (2005), 1034–1039.
112. [112] Yang, J., et al. Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-beta1 signaling. J. Am. Soc. Nephrol. 14:12 (2003), 3167–3177.
113. [113] Yang, J., Dai, C., Liu, Y., A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J. Am. Soc. Nephrol. 16:1 (2005), 68–78.
114. [114] Yang, J., Liu, Y., Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am. J. Physiol. Renal. Physiol. 284:2 (2003), F349–F357.
115. [115] Choi, M.E., Ding, Y., Kim, S.I., TGF-beta signaling via TAK1 pathway: role in kidney fibrosis. Semin. Nephrol. 32:3 (2012), 244–252.
116. [116] Ge, B., et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 295:5558 (2002), 1291–1294.
117. [117] Adhikary, L., et al. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47:7 (2004), 1210–1222.
118. [118] Stambe, C., et al. The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J. Am. Soc. Nephrol. 15:2 (2004), 370–379.
119. [119] Ma, F.Y., et al. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J. Am. Soc. Nephrol. 18:2 (2007), 472–484.
120. [120] Sebe, A., et al. Transforming growth factor-beta-induced alpha-smooth muscle cell actin expression in renal proximal tubular cells is regulated by p38beta mitogen-activated protein kinase, extracellular signal-regulated protein kinase1,2 and the Smad signalling during epithelial-myofibroblast transdifferentiation. Nephrol. Dial. Transplant. 23:5 (2008), 1537–1545.
121. [121] Sorrentino, A., et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10:10 (2008), 1199–1207.
122. [122] Yamashita, M., et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell 31:6 (2008), 918–924.
123. [123] Yang, L., et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 16:5 (2010), 535–543 1p following 143.
124. [124] Hasan, M., et al. Activation of TGF-beta-induced non-Smad signaling pathways during Th17 differentiation. Immunol. Cell Biol. 93:7 (2015), 662–672.
125. [125] Hartsough, M.T., Mulder, K.M., Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J. Biol. Chem. 270:13 (1995), 7117–7124.
126. [126] Li, Y., et al. Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J. Am. Soc. Nephrol. 20:9 (2009), 1907–1918.
127. [127] Yoshino, J., et al. Snail1 is involved in the renal epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun. 362:1 (2007), 63–68.
128. [128] Imamichi, Y., Menke, A., Signaling pathways involved in collagen-induced disruption of the E-cadherin complex during epithelial-mesenchymal transition. Cells Tissues Organs 185:1–3 (2007), 180–190.
129. [129] Deng, B., et al. Focal adhesion kinase mediates TGF-beta1-induced renal tubular epithelial-to-mesenchymal transition in vitro. Mol. Cell. Biochem. 340:1–2 (2010), 21–29.
130. [130] Tian, Y.C., Phillips, A.O., Interaction between the transforming growth factor-beta type II receptor/Smad pathway and beta-catenin during transforming growth factor-beta1-mediated adherens junction disassembly. Am. J. Pathol. 160:5 (2002), 1619–1628.
131. [131] Zhou, B., et al. Interactions between beta-catenin and transforming growth factor-beta signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J. Biol. Chem. 287:10 (2012), 7026–7038.
132. [132] Guo, L., et al. Hydrogen sulfide inhibits transforming growth factor-beta1-induced EMT via Wnt/catenin pathway. PLoS ONE, 11(1), 2016, e0147018.
133. [133] Loeffler, I., Wolf, G., Transforming growth factor-beta and the progression of renal disease. Nephrol. Dial. Transplant. 29:Suppl 1 (2014), i37–i45.
134. [134] Mahimainathan, L., et al. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 55:7 (2006), 2115–2125.
135. [135] Choudhury, G.G., A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cepsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1alpha transcriptional activation. J. Biol. Chem. 279:26 (2004), 27399–27409.
136. [136] Kato, M., et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell Biol. 11:7 (2009), 881–889.
137. [137] Chung, A.C., et al. Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Mol. Ther. 21:2 (2013), 388–398.
138. [138] Sharma, K., et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:4 (1996), 522–530.
139. [139] Benigni, A., et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14:7 (2003), 1816–1824.
140. [140] Gagliardini, E., Benigni, A., Role of anti-TGF-beta antibodies in the treatment of renal injury. Cytokine Growth Factor Rev. 17:1–2 (2006), 89–96.
141. [141] Akagi, Y., et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 50:1 (1996), 148–155.
142. [142] Isaka, Y., et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int. 58:5 (2000), 1885–1892.
143. [143] Miric, G., et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol. 133:5 (2001), 687–694.
144. [144] Misra, H.P., Rabideau, C., Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem. 204:1–2 (2000), 119–126.
145. [145] Shimizu, T., et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 54:1 (1998), 99–109.
146. [146] Shimizu, T., et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int. Suppl. 63 (1997), S239–S243.
147. [147] RamachandraRao, S.P., et al. Pirfenidone is renoprotective in diabetic kidney disease. J. Am. Soc. Nephrol. 20:8 (2009), 1765–1775.
148. [148] Cho, M.E., et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2:5 (2007), 906–913.
149. [149] Sharma, K., et al. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22:6 (2011), 1144–1151.
150. [150] Akhurst, R.J., Hata, A., Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug Discov. 11:10 (2012), 790–811.
151. [151] Jinnin, M., Ihn, H., Tamaki, K., Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol. Pharmacol. 69:2 (2006), 597–607.
152. [152] Li, J., et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 59:10 (2010), 2612–2624.
153. [153] Lan, H.Y., Smad7 as a therapeutic agent for chronic kidney diseases. Front. Biosci. 13 (2008), 4984–4992.
154. [154] Wang, S., et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int. 63:6 (2003), 2037–2049.
155. [155] Wang, S., et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J. Am. Soc. Nephrol. 17:9 (2006), 2504–2512.
156. [156] Mitu, G., Hirschberg, R., Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Front. Biosci. 13 (2008), 4726–4739.
157. [157] Yanagita, M., et al. Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J. Clin. Invest. 116:1 (2006), 70–79.
158. [158] Sugimoto, H., et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat. Med. 18:3 (2012), 396–404.
159. [159] Harney, A.S., Meade, T.J., LaBonne, C., Targeted inactivation of Snail family EMT regulatory factors by a Co(III)-Ebox conjugate. PLoS ONE, 7(2), 2012, e32318.
160. [160] Roa, H., et al. Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats. FEBS Lett. 583:19 (2009), 3192–3198.
161. [161] Quezada, C., et al. 5’-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells. J. Cell. Physiol. 228:3 (2013), 602–608.
162. [162] Shull, M.M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:6397 (1992), 693–699.